Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study

被引：0
作者：
Longo, Raffaele [1 ]
Thiebaut, Victoire [1 ]
Legros, Pierre-Olivier [1 ]
Campitiello, Marco [1 ]
Plastino, Francesca [1 ]
Goetz, Christophe [2 ]
Margineanu, Bogdan [3 ]
Pujois, Julie [3 ]
Gunther, Michel [3 ]
Egea, Julie [1 ]
Wendel, Chloe [1 ]
机构：
[1] CHR Metz Thionville, Div Med Oncol, 1 Allee Chateau, F-57085 Ars Laquenexy, France
[2] CHR Metz Thionville, Clin Res Support Unit, Ars Laquenexy, France
[3] CHR Metz Thionville, Div Gynecol, Ars Laquenexy, France
来源：
ACTA ONCOLOGICA | 2022年 / 61卷 / 11期
关键词：
OPEN-LABEL; PLUS TRASTUZUMAB; LAPATINIB; SAFETY; CHEMOTHERAPY; EFFICACY; RECOMMENDATIONS; MULTICENTER; PERTUZUMAB; THERAPY;
D O I：
10.1080/0284186X.2022.2132115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1394 / 1399
页数：6
相关论文
共 50 条
  • [31] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [32] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
  • [33] Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar
    Agostinetto, Elisa
    Curigliano, Giuseppe
    Piccart, Martine
    CELL REPORTS MEDICINE, 2024, 5 (06)
  • [34] Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Dempsey, Naomi
    Sandoval, Ana
    Mahtani, Reshma
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) : 1120 - 1137
  • [35] Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
    Ciruelos, Eva
    Villagrasa, Patricia
    Pascual, Tomas
    Oliveira, Mafalda
    Pernas, Sonia
    Pare, Laia
    Escriva-de-Romani, Santiago
    Manso, Luis
    Adamo, Barbara
    Martinez, Eduardo
    Cortes, Javier
    Vazquez, Silvia
    Perello, Antonia
    Garau, Isabel
    Mele, Mireia
    Martinez, Noelia
    Montano, Alvaro
    Bermejo, Begona
    Morales, Serafin
    Echarri, Maria J.
    Vega, Estela
    Gonzalez-Farre, Blanca
    Martinez, Debora
    Galvan, Patricia
    Canes, Jordi
    Nuciforo, Paolo
    Gonzalez, Xavier
    Prat, Aleix
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5820 - 5829
  • [36] Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer
    Otoya, Iris
    Valdiviezo, Natalia
    Morante, Zaida
    Calle, Cindy
    Ferreyra, Yomali
    Huarcaya-Chombo, Norma
    Polo-Mendoza, Gabriela
    Castaneda, Carlos
    Vidaurre, Tatiana
    Neciosup, Silvia P.
    Calderon, Monica J.
    Gomez, Henry L.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2024, 2024
  • [37] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [38] Neratinib for the treatment of HER2-positive early stage breast cancer
    Echavarria, Isabel
    Lopez-Tarruella, Sara
    Marquez-Rodas, Ivan
    Jerez, Yolanda
    Martin, Miguel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 669 - 679
  • [39] Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
    Wu, Jiong
    Jiang, Zefei
    Liu, Zhenzhen
    Yang, Benlong
    Yang, Hongjian
    Tang, Jinhai
    Wang, Kun
    Liu, Yunjiang
    Wang, Haibo
    Fu, Peifen
    Zhang, Shuqun
    Liu, Qiang
    Wang, Shusen
    Huang, Jian
    Wang, Chuan
    Wang, Shu
    Wang, Yongsheng
    Zhen, Linlin
    Zhu, Xiaoyu
    Wu, Fei
    Lin, Xiang
    Zou, Jianjun
    BMC MEDICINE, 2022, 20 (01)
  • [40] Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience
    Tiwari, A.
    Gogia, A.
    Deo, S. V. S.
    Shukla, N. K.
    Mathur, S.
    Sharma, D. N.
    INDIAN JOURNAL OF CANCER, 2017, 54 (01) : 343 - 346
12345